Clinical Director, Division of Cancer Genetics and Prevention
Senior Physician, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Huma Q. Rana, MD, MPH is the Clinical Director
of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer
Institute, and Assistant Professor of Medicine at Harvard Medical School. At
Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical
management and the clinical operations that provide care to individuals with
rare genetic susceptibilities to cancer.
In addition to her clinical work, Dr. Rana leads
multiple clinical research projects focused on developing cancer prevention and
screening for those with hereditary cancer risk, and novel approaches to
improving access to cancer genetics services.
Dr. Rana received her medical degree from the Rutgers
Robert Wood Johnson Medical School, completed her residencies in Internal
Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai,
and received her MPH from the Harvard T.H. Chan School of Public Health. She has been a member of the Dana-Farber
faculty since 2012.
Clinical Director, Division of Cancer Genetics and Prevention
Senior Physician, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Huma Q. Rana, MD, MPH is the Clinical Director
of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer
Institute, and Assistant Professor of Medicine at Harvard Medical School. At
Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical
management and the clinical operations that provide care to individuals with
rare genetic susceptibilities to cancer.
In addition to her clinical work, Dr. Rana leads
multiple clinical research projects focused on developing cancer prevention and
screening for those with hereditary cancer risk, and novel approaches to
improving access to cancer genetics services.
Dr. Rana received her medical degree from the Rutgers
Robert Wood Johnson Medical School, completed her residencies in Internal
Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai,
and received her MPH from the Harvard T.H. Chan School of Public Health. She has been a member of the Dana-Farber
faculty since 2012.
Journal article
Background/Objectives: An accurate evaluation of variant actionability is essential in cancer management. In Von Hippel-Lindau Syndrome (VHL), the interpretation of the germline variants is confounded by the presence of non-syndromic component tumors, such as clear cell renal cell carcinoma (ccRCC), hemangioblastoma, pheochromocytoma, and neuroendocrine tumors. These tumors frequently occur sporadically, without any association with VHL syndrome. The presence of these tumors in a patient with a...
Journal article
CONCLUSION: This study reveals high geographic variability in tissue-based biomarker testing for prostate cancer. Further, Black and Hispanic patients were less likely to receive testing. Our findings highlight regional practice variation in the use of advanced, not routinely recommended tests and underscore the need to minimize disparities in diagnostic access.